Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q2 FY26 Earnings Presentation
28 slides from Jubilant Ingrevia's earnings presentation, October 2025
Slide 1: Investor Presentation October 2025
Investor Presentation October 2025 Innovating for a Sustainable Future 1
Slide 2: Forward-looking statements and notes
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product
Slide 3: Chairman's message and markets update
“We are pleased to share the financial results for the second quarter of this fiscal year. Our Speciality Chemicals segment continues to drive the growth momentum with double digit YoY revenue growth and a positive growth over last quarter. Our Nutrition business maintained a steady volume growth tr
Slide 4: Business Update
Business Update: The Specialty Chemicals segment continued on its revenue growth trajectory and reported 25%+ margins during the quarter, driven primarily by strong performance in Fine Chemicals and CDMO sales. We successfully delivered volumes against one of our new Agro CDMO innovator contract in
Slide 5: Table of Contents
Table of Contents 0 6 Company Overview 1 3 Q2’FY26 Highlights 1 9 Business Segments Update 5
Slide 6: Company Overview
Ww JUBHANT INGREVIA Company Overview. - p) Oe Bae!
Slide 7: Transformation into Specialty Leader
Transformation into Forward Specialty Leader Expansion & Integration 2023 onwards Origin Diversification 2011 - 2023 1978 – 1990 1990 – 2011 • Expansion of Pyridine • Started as VAM • Forward integration into • Foray into Pyridine derivatives Organics Pyridine derivatives Chemistry • Foray into Dike
Slide 8: Business segments and products
1 2 3 Specialty Nutrition Chemical Chemicals & Health Solutions Intermediates • CDMO • Fine Chemicals • Animal Nutrition and Health Solutions • Acetic Anhydride • Acetaldehyde • Pyridine and Picolines • Human Nutrition Solutions • Ethyl Acetate • Bio Acetic Acid Globally #1 Globally #2 Globally #2 •
Slide 9: Nutrition & Health Solutions
Consumer ROW Nutrition 5% 11% & Health Agro North Solutions 22% Pharma America 8% 17% Specialty 32% India Chemicals 57% 45% Europe Chemical Industrial 24% Intermediates 20% 39% Nutrition 22% 9
Slide 10: 2300+ people, 130+ products, 1500+ customers
Gajraula Bharuch Nira Savli Ambernath Uttar Pradesh, India Gujarat, India Maharashtra, India Gujarat, India Maharashtra, India Integrated facility for CDMO & Fine Chemicals Chemical Intermediates Animal Nutrition Microbial Control Specialty Chemicals & Nutrition and Chemical Facility & Health Soluti
Slide 11: R&D Centers, Scientists, PhDs
R&D Center G. Noida UP, India Pilot Plant at Gajraula UP, India 3 ~150 ~30 R&D Centers Scientists PhDs 11
Slide 12: Business Leaders
SS Bhartia HS Bhartia Deepak Jain Chairman Co-Chairman & Whole CEO & MD Time Director 20 yrs exp Business Leaders Function Leaders Specialty Chemicals Nutrition & Health Chemical Intermediates Varun Gupta Vijay Kumar Srivastava Ambrish Dixit Ashish Kr. Sinha Himanshu Dhapola President, Chief Preside
Slide 13: Q2'FY26 Highlights
Q2’FY25 Highlights - 2 . ale!
Slide 14: Pharma, Agrochem, Nutrition market update
PHARMA • Volumes remained steady across segments, especially in our core products in Fine Chemicals • Prices remained stable in most segments; Customers await clarity on tariff situation thus delaying decisions in a few opportunities • Paracetamol segment volumes witnessed moderate growth, with all
Slide 15: Business, Customer, Operations / ESG
Business Customer Operations / ESG • Overall: Highest Quarterly Revenue, Sales • KAM: Opportunity funnel expansion to • Green power impact showing up: volume in last 10 quarters 100+ (70 in Q1) Power & Fuel expense dropped 16% • Acetyls: Highest revenue and volumes in • Confirmed: 10+ molecules in l
Slide 16: Consolidated financial summary
Particulars1 Q2'FY25 Q1'FY26 Q2'FY26 Q-o-Q Y-o-Y H1'FY25 H1'FY26 Y-o-Y Total Revenue 1,045 1,038 1,121 8% 7% 2,070 2,159 4% Total EBITDA 135 153 146 -5% 8% 254 300 18% EBITDA Margin (%) 13% 15% 13% 12% 14% Profit After Tax 59 75 70 -7% 18% 108 145 34% Profit After Tax Margin (%) 6% 7% 6% 5% 7% Basic
Slide 17: Segment-wise EBITDA Share (%)
Segment-wise EBITDA Share (%) 6% 13% 10% 12% 25% 27% 17% 36% 36% 14% 13% 43% 40% 15% 48% 46% 45% 49% 16% 16% 7% 14% 5% 14% 8% 4% 13% 12% 76% 76% 75% 72% 56% 59% 57% 52% 50% 46% 47% 46% 40% 43% Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Specialty
Slide 18: Segment EBITDA: Specialty Chemicals, Nutrition, Chemical Intermediates
Specialty Chemicals Nutrition Chemical Intermediates EBITDA (Rs Cr.) EBITDA (Rs Cr.) EBITDA (Rs Cr.) Y.o.Y Growth 44% Y.o.Y De-Growth -13% Y.o.Y Growth -51% Q.o.Q De-Growth -4% Q.o.Q De-Growth -15% Q.o.Q Growth 18% 130 40 125 24 25 21 87 20 27% 26% 14% 17 13% 20% 12% 9% 4% 4% Q2 FY25 Q1 FY26 Q2 FY26
Slide 19: Business Segments Overview
Business Segments Overview 19
Slide 20: Specialty Chemicals: Pharma, Agrochemical, CDMO/FC
1 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Pharma End-use demand continued to show positive momentum, improvement witnessed Particulars1 Q2'FY25 Q1'FY26 Q2'FY26 Q-o-Q Y-o-Y H1'FY25 H1'FY26 Y-o-Y on YoY and QoQ basis Segment Revenue 433 478 485 1% 12% 864 963 11% - Pricing remained stable and consist
Slide 21: Nutrition: Feed B3, Choline
2 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Market demand remained steady with Q1 roll-over orders creating marginal uptick Particulars1 Q2'FY25 Q1'FY26 Q2'FY26 Q-o-Q Y-o-Y H1'FY25 H1'FY26 Y-o-Y - Competition volume push weighed on Segment Revenue 182 179 181 1% -1% 368 359 -2% Feed B3 global prices.
Slide 22: Chemical Intermediates: Volumes, Cost, Price
3 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS - Increase in India market volumes with marginal uptick in agro and paracetamol Particulars1 Q2'FY25 Q1'FY26 Q2'FY26 Q-o-Q Y-o-Y H1'FY25 H1'FY26 Y-o-Y Segment Revenue 430 381 455 20% 6% 838 836 0% - Continued market challenges in Europe, Volumes driven by wea
Slide 23: Annexures
Annexures 23
Slide 24: Consolidated income statement
Particulars1 Q2'FY25 Q1'FY26 Q2'FY26 QoQ YoY H1'FY25 H1'FY26 YoY Revenue from operations a) Sales/Income from operations 1029 1029 1110 8% 8% 2039 2139 5% b) Other operating income 16 9 11 30% -32% 30 20 -35% Total revenue from operations 1045 1038 1121 8% 7% 2070 2159 4% Other income 10 11 11 -4% 3
Slide 25: Segment revenue, EBITDA and margins
Particulars1 Q2'FY25 Q1'FY25 Q2'FY26 QoQ (%) YoY (%) H1'FY25 H1'FY26 YoY (%) Total Revenue from Operations 1,045 1,038 1,121 8% 7% 2,070 2,159 4% Speciality Chemicals 433 478 485 1% 12% 864 963 11% Nutrition & Health Solutions 182 179 181 1% (1%) 368 359 (2%) Chemical Intermediates 430 381 455 20% 6
Slide 26: Debt and capex
Particulars1 30-Sep-24 31-Mar-25 30-Sep-25 Long Term Borrowings 450 453 458 Short Term Borrowings 263 303 336 Total Gross Debt 713 756 794 Cash & Equivalent 63 98 47 Total Net Debt 650 658 748 YoY change 15% • The capex for the quarter was Rs 59 Crore, which was primarily utilized towards the upcomi
Slide 27: Earnings conference call details
Date : October 27th, 2025 Diamond Pass Log-In Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, passcode and a pin for the concall on th
Slide 28: Thank you for your time
Jubilant Ingrevia Limited is a leading player in Specialty Chemicals For Investors: globally, serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It has a broad portfolio of over 130+ Pavleen Taneja products and customized solutions that are innovative, cost-effective